Floatz Rating
D30/100
Confidence
Indicative
Sponsor
BioDelivery Sciences International
Modality
Small molecule
Development Phase
Unknown
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03720613CT.gov Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Opioid-Induced Constipation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Naloxegol (this asset) | BioDelivery Sciences International | Unk | D · 30 |
| Naldemedine | BioDelivery Sciences International | P3 | BBB |
| Methylnaltrexone | Bausch Health Americas, Inc. | P3 | B |
| Prucalopride | Shire | P3 | B |
| Rdc-1036 | Alkermes, Inc. | P2 | B |
| Morphinan-3,6,14-Triol, 4,5-Epoxy-17-(2-Propenyl)-, (5.Alpha.,6.Beta.)- | S.L.A. Pharma AG | P2 | B |
| Linaclotide | Forest Laboratories | P2 | B |
| Lactobacillus Gasseri Bgp345A | BioGaia Pharma AB | P2 | B |
| Bevenopran | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | P3 | CCC |
+2 more in the Opioid-Induced Constipation cohort
Other indications for Naloxegol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Brain Injury | — | P3 | CCC · 53 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 49 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Naloxegol in Opioid-Induced Constipation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/naloxegol-opioid-induced-constipation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →